

October 5, 2024

| | |
|---|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|---|--|

Dear Sir/Madam,

Sub: Disposal of entire 50% shares held in Novagen Pharma (Pty) Ltd., South Africa, a joint venture company.

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, we hereby inform you that Aurogen South Africa (Pty) Ltd., (Aurogen) a wholly owned step-down subsidiary of the Company in South Africa, has entered into an agreement with Novabee Proprietary Limited, to sell and dispose of the entire 50% shares held by Aurogen in Novagen. After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, is enclosed as “**Annexure**”.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl.: Annexure

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

| Sl No. | Particulars | Description | | | |
|--------|---|---|----------------|----------------|---|
| | | Aurogen share in Novagen | ZAR in million | INR in million | % of listed entity during last financial year |
| a) | the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year(s); | Revenue | 49.4 | 218.3 | 0.08% |
| | | Net worth | 12.4 | 54.4 | 0.02% |
| b) | date on which the agreement for sale has been entered into; | October 4, 2024 | | | |
| c) | the expected date of completion of sale/disposal; | October 4, 2024 | | | |
| d) | consideration received from such sale/disposal; | ZAR 7 million (INR 33.53 million) of which ZAR 5 million (INR 23.95 million) will be paid upfront and balance ZAR 2 million (INR 9.58 million) will be paid after end of 12 months. | | | |
| e) | brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof; | <p>Novagen Pharma (Pty) Ltd. (Novagen), a pharmaceutical company incorporated in March 2009 and based in Pretoria, South Africa is a joint venture company between Aurogen South Africa (Pty) Ltd., (Aurogen), a wholly owned step-down subsidiary of the Company in South Africa and Clinigen South Africa Pty Ltd., South Africa (Clingen). Novagen markets a comprehensive range of generic antiretroviral and chronic products in the South African pharmaceutical market.</p> <p>50% shares of Novagen are held by Aurogen and the balance 50% of the shares in Novagen are held by Clinigen.</p> <p>Novabee is a private limited company registered under the laws of Republic of South Africa.</p> <p>Novabee, the buyers, does not belong to the promoter/ promoter group/group companies of the Company.</p> | | | |
| f) | whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”; | The transaction would not fall within related party transactions. | | | |

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833

Email: info@aurobindo.com Website: www.aurobindo.com

| | | |
|----|--|--|
| g) | whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. | Not applicable since the proposed sale or disposal of shares will not amount to sale or disposal of the whole or substantially the whole of the undertaking. |
| h) | additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale. | Not applicable. |

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833
 Email: info@aurobindo.com Website: www.aurobindo.com